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Multidrug resistant (MDR) bacteria are an increasing health problem with the shortage
of new active antibiotic agents. Among effective mechanisms that contribute to the
spread of MDR Gram-negative bacteria are drug efflux pumps that expel clinically
important antibiotic classes out of the cell. Drug pumps are attractive targets to
restore the susceptibility toward the expelled antibiotics by impairing their efflux activity.
Arylhydantoin derivatives were investigated for their potentiation of activities of selected
antibiotics described as efflux substrates in Enterobacter aerogenes expressing or not
AcrAB pump. Several compounds increased the bacterial susceptibility toward nalidixic
acid, chloramphenicol and sparfloxacin and were further pharmacomodulated to obtain
a better activity against the AcrAB producing bacteria.
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INTRODUCTION
Multidrug resistance (MDR) described in Gram-negative bacteria is continuously emerging as a
prominent worldwide health concern (Chopra et al., 2008; Laxminarayan et al., 2008; Gandhi et al.,
2010). One of the most contributing mechanisms is the overexpression of eﬄux pumps that are
involved in bacterial survival, colonization and virulence (Delmar et al., 2014; Blair et al., 2015;
Li et al., 2015; Venter et al., 2015; Davin-Regli et al., 2016). Several eﬄux pump superfamilies,
e.g., major-facilitator (MF), multi-drug and toxic eﬄux (MATE), ATP-binding cassette (ABC),
small multidrug resistance (SMR), resistance-nodulation-division (RND) transporters have been
classified1,2 and extensively described in well-documented reviews: they differ by their functional
structure and organization, their subcellular location inside the bacterium, their energy source (e.g.,
membrane potential for RND or ATP for ABC) and the involvement of a coupled antiport during
the antibiotic expulsion (e.g., proton for AcrAB pump; Delmar et al., 2014; Blair et al., 2015; Li
et al., 2015). The overexpression of Gram-negative eﬄux pumps, especially those belonging to the
1http://www.membranetransport.org/
2http://www.tcdb.org/
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RND family, is now well-described in resistant isolates
(Nikaido and Pagès, 2012; Li et al., 2015). This contributes
to the acquisition of additional mechanisms of resistance
including the mutation in antibiotic targets (e.g., mutation
in gyrase/topoisomerase for quinolone) or the production
of enzymes that degrade antibiotics (e.g., β-lactamases) and
this can be associated or not with the alteration of the outer
membrane permeability (Davin-Regli et al., 2008; Pagès et al.,
2008). Regarding resistant clinical isolates of Gram-negative
bacteria, the archetype of the drug active transporter system
is the AcrAB-TolC/MexAB-OprM eﬄux pumps (Nikaido and
Pagès, 2012; Li et al., 2015). The structures of components of
eﬄux systems belonging to RND group, have been solved by
X-ray crystallography and models of the pump assembly have
been obtained (Yao et al., 2010; Du et al., 2014). The structure
and function of the RND eﬄux pumps must be molecularly
deciphered thus allowing the rational design and the synthesis
of new compounds to combat MDR. The broad selectivity
of eﬄux pumps makes difficult the identification of precise
pharmacophoric groups at the drug surface. However, eﬄux
pumps are attractive target by blocking this eﬄux mechanism in
order to restore the intracellular concentration of antibacterial
agents (Bolla et al., 2011; Ruggerone et al., 2013; Dreier and
Ruggerone, 2015; Opperman and Nguyen, 2015). Recent
computer docking analyses have produced some information
about the involvement of certain amino acid residues, but
clearly more chemical and biological information are needed
to improve models (Schulz et al., 2010; Fischer et al., 2014).
This is a ‘key’ point not only regarding the mode of action
and dynamics of the process but also regarding the clinical
impact of the design of new antibacterial agents: this last aspect
is illustrated by the β-lactamases inhibitors currently used
today (Bolla et al., 2011; Chen et al., 2013; Pucci and Bush,
2013).
To enhance the activity of old antibiotics by targeting
resistance mechanisms in clinical resistant isolates, they can
be combined with adjuvant molecules such as chemosensitizers
(e.g., membrane permeabilizer or eﬄux inhibitor; Jones, 2010;
Bolla et al., 2011). In addition, these types of transporter
inhibitors may impair the activity of eﬄux pumps and thus
reduce bacterial colonization and virulence (Venter et al., 2015;
Davin-Regli et al., 2016). It must be noted that the efficacy
of the inhibitors depends on their affinity for transporter
binding sites (compared to the antibiotic) and their internal
concentration close to the eﬄux pump. Consequently, due to
these parameters associated with penetration rate and affinity
for pump sites, some discrepancies can be observed in the
level of the internally accumulated antibiotics depending on the
bacterial backgrounds (Kašcˇáková et al., 2012; Cinquin et al.,
2015).
Recently, two generations of hydantoin derivatives have
been identified as AcrAB-TolC inhibitors with the Enterobacter
aerogenes CM 64 strain that overproduces AcrAB (Handzlik
et al., 2011). Compounds showing chemosensitizing effect
on nalidixic acid activity were the starting point for new
pharmacomodulations carried out in this study to obtain
a new generation of products with an improved activity.
Moreover, tests were extended to other chemically unrelated
antibiotics, chloramphenicol and sparfloxacin, for which the
antibacterial activity decreased together with the emergence
of multidrug-resistant strains. Several chemical derivatives
were synthesized to define pharmacophoric groups important
for restoring the activity of antibiotics in AcrAB active
bacteria.
MATERIALS AND METHODS
Bacterial Strains
All generations of hydantoin derivatives were tested against
two strains of E. aerogenes: the reference strain, ATCC 13048
(basal eﬄux producer) and its derivative strain, CM 64, a
chloramphenicol-selected resistant strain that over-produces the
AcrAB-TolC EPs (Ghisalberti et al., 2005). In addition, two
isogenic strains EA289 (a clinical MDR strain that overproduced
the AcrAB pump) and its EA294 derivative (an acrAB knockout
strain) were used (Pradel and Pagès, 2002). These two strains
contain additional mechanisms of antibiotic resistance such as ß-
lactamases, targets mutations, etc. (Malléa et al., 1998; Pradel and
Pagès, 2002; Kašcˇáková et al., 2012).
Chemicals
Hydantoin derivatives used in the pharmacological assays were
obtained by chemical synthesis. The new generations IIIA and
B were obtained using 3–4-step synthesis (Handzlik et al.,
2014; Matys et al., 2015; Figure 1 and Supplementary data).
Purity and identity of new compounds were confirmed using
spectral analysis (H-NMR, IR), elemental analysis and melting
point measurements. Phenylalanine-Arginine β-naphthylamide
(PAβN, dihydrochloride, Sigma) previously described as eﬄux
pump inhibitor was used as reference (Bolla et al., 2011; Misra
et al., 2015).
Compound Susceptibility Assays
Susceptibilities of ATCC 13048, CM 64, EA294, and EA289 were
determined by using the twofold standard microbroth dilution
method (microplates and automatic analyses Tecan R©; CLSI3).
Approximately, 105 CFU (colony forming unit) were inoculated
in 200 µl of Mueller-Hinton II broth (MH II broth cation
adjusted, Becton, Dickinson & Company) containing twofold
serial dilutions of the targeted molecule. Experiments were
performed in triplicate for each compound and each antibiotic.
Results were estimated visually after 18 h incubation at 37◦C
(Philippe et al., 2015).
Antibiotic Susceptibility Potentiating
Assays
To assay the possible chemosensitizing activity of compounds,
serial dilutions of antibiotics, nalidixic acid (NAL, Sigma),
chloramphenicol (CHL, Sigma), doxycycline (DOX, hyclate,
Sigma), erythromycin (ERY, lactobionate, AMDIPHARM) and
3http://clsi.org/
Frontiers in Microbiology | www.frontiersin.org 2 May 2016 | Volume 7 | Article 622
fmicb-07-00622 April 29, 2016 Time: 12:49 # 3
Otre˛bska-Machaj et al. Hydantoin Based-Modulators of Efflux Pump
FIGURE 1 | Compounds of generation IIIA and generation IIIB of hydantoins.
sparfloxacin (SPX, Sigma), were incubated in the absence or
in the presence of compounds. The antibiotics, NAL, CHL,
and SPX are substrates of the AcrAB-TolC eﬄux pump as
demonstrated by the increased MIC values obtained in CM
64 strain overexpressing the AcrAB-TolC pump (Table 1)
TABLE 1 | Susceptibility (MIC) of the Enterobacter aerogenes reference
strain ATCC 13048, the derivative strain CM 64 overexpressing
AcrAB-TolC pump, Ea289 overproducing the AcrAB pump and its
derivative Ea294 (an acrAB knockout strain) to the different compounds
belonging to various generations of hydantoins and to nalidixic acid
(NAL), chloramphenicol (CHL), sparfloxacin (SPX), doxycycline (DOX), and
erythromycin (ERY).
Compound MIC [mM]
ATCC 13048
MIC [mM]
CM 64
MIC [mM]
Ea294
MIC [mM]
Ea289
29–36 >2 >2 >1 >1
NAL 0.034 0.55 (16)∗ 4.4 >17.6
CHL 0.012 0.79 (66) 0.2 3.2
SPX 0.00015 0.0025 (17) >2 >2
DOX 0.002 0.07 (35) 0.002 0.07
ERY 0.35 0.7 (2) 0.087 0.35
PAβN 5 5 (1) 0.0625 3.5
∗MIC ratio: efflux overproducer/basal producer strains.
compared to the reference one ATCC 13048. Thus we are
able to hypothesize that an eﬄux blocker may reduce the
antibiotic MIC in eﬄux producer strain. Generations IIIA and
IIIB of hydantoin derivatives were tested at a concentration
of 0.5 mM according to the intrinsic antibacterial activity
of each compound (corresponding to the value of MIC/4).
To facilitate the comparison of activity and the performance
of a rational SAR analysis, they were additionally tested at
the concentration corresponding to that of the best first
generation of chemosensitizers (0.0625 mM; Handzlik et al.,
2011). PAβN, the reference inhibitor for AcrAB pump, was
used at 0.050 mM. Control experiments were carried out
without compounds. Experiments were performed in triplicate
for each antibiotic, each strain and each condition (without
and with compound). The results were assessed after 18 h at
37◦C and were presented by using the activity gain parameter
A, the ratio of the MIC of the antibiotic (determined in the
absence of compound) to its MIC in the presence of the
compound.
Determination of the FIC Index
To determine the fractional inhibitory concentration index
(FICi), a two dimensional checkerboard with twofold dilutions
of each compound was set up for the study (Berenbaum, 1978;
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TABLE 2 | Effect of the hydantoin derivatives on the susceptibility level of E. aerogenes ATCC 13048 and CM 64 strains to nalidixic acid (NAL),
chloramphenicol (CHL), and sparfloxacin (SPX).
Compound Concentration [mM] A NAL A CHL A SPX
ATCC 13048 CM 64 ATCC 13048 CM 64 ATCC 13048 CM 64
29 0.0625 1 1 1 1 2 2
30 “ 2 2 2 1 1 1
31 “ 2 2 2 1 1 2
32 “ 2 4 1 1 1 2
33 “ 1 1 1 1 1 1
34 “ 1 0.5 0.5 1 0.5 1
35 “ 1 1 0.5 1 0.5 0.5
36 “ 1 1 1 1 0.5 0.5
29 0.5 8 4 2 4 4 2
30 “ 8 4 4 4 8 4
31 “ 16 4 4 4 4 4
32 “ 16 32 4 32 8 8
33 “ 2 2 1 2 2 1
34 “ 2 1 1 1 2 2
35 “ 2 1 2 1 2 1
36 “ 2 1 2 1 2 1
PAβN 0.05 64 128 2 64 8 32
“A” corresponds to the antibacterial activity gain obtained in the presence of the respective compound and evaluated for each antibiotic (A =MIC without compound/MIC
with compound).
Allam et al., 2014). For the first clear well in each row of
the microplate containing an antimicrobial agent, the FIC was
calculated as follows: FIC of compound A (FIC A) = MIC of
compound A in combination with B/MIC of compound A alone,
and FIC of compound B (FIC B) = MIC of compound B in
combination with A/MIC of compound B alone. The FICi was
calculated as the sum of the FIC of each compound. The nature
of the interaction was classified as follows: synergy FICi ≤ 0.5;
additivity 0.5 < FICi ≤ 1; indifference 1 < FICi ≤ 2; and
antagonism FICi > 2 (European Committee for Antimicrobial
Susceptibility Testing (EUCAST) of the European Society of
Clinical Microbiology and Infectious Diseases (ESCMID), 2000).
For each combination, an isobologram, which graphically
illustrates the interaction effect, was constructed: FIC A was
showed in the abscissa and FIC B in the ordinate, the
profile of the corresponding curve reflects the nature of the
interaction.
RESULTS
Antibacterial Activity
It is important that putative inhibitors that could be used
as “adjuvant molecule” for antibiotics, do not display a high
intrinsic antibacterial activity (Davin-Regli et al., 2008; Bolla
et al., 2011). The determination of the antibacterial activity for
each compound was performed and presented in Table 1. Many
of the compounds did not inhibit the growth of bacteria even
at the highest tested concentration as the previous generations
of hydantoin derivatives (Handzlik et al., 2011). The majority
of compounds exhibited a MIC > 2 mM in ATCC13048
and in CM64 strains and MIC ≥ 1 mM in Ea289 and
Ea294.
Influence on Antibiotic Susceptibility in
ATCC 13048 and CM 64 Strains
Effect on Nalidixic Acid Susceptibility
Table 2 presents the chemosensitizing effect of compounds
on ATCC 13048 and CM 64 susceptibility to nalidixic acid
(NAL). The gain on antibiotic activity (A) was calculated for
each compound and each antibiotic. Regarding the CM 64
strain, a moderate or a weak effect was observed on the MIC
when compounds were used at 0.0625 mM compared to PAβN.
Compounds of generations IIIA (29–32) and IIIB (33–36) were
used at a concentration of 0.0625 mM and 0.5 mM due to
their higher MIC. A higher concentration of compounds of the
generation IIIB did not improve the antibiotic activity whereas we
observed a significant decrease of the antibiotic MIC, from 4- to
32-fold in CM 64 (see ANAL in Table 2), in the case of compounds
of generation IIIA (29–32). These compounds decreased the MIC
of NAL from 8- to 16-fold comparing to the PAβN effect (64-
fold) in the reference ATCC 13048 strain (see ANAL in Table 2).
In the case of PAβN and derivatives 32 the difference in activity
in both tested strains was not significant (only a twofold stronger
activity in the strain overexpressing the AcrAB pump than in the
reference one) whereas compounds 29–31 showed a better action
on antibiotic activity in the reference strain. It must be noted
that the compound 32 used at increased concentration exhibits
an activity profile similar to PAßN, which has been shown to be
an efficient eﬄux inhibitor at low concentrations (Nikaido and
Pagès, 2012; Misra et al., 2015).
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TABLE 3 | Effect of the compounds of generation IIIA (29–32) depends on AcrAB context.
Compound Ea294 Ea289 CM 64
ADOX AERY ANAL ADOX AERY ANAL ADOX AERY
29 2 1 2 8 1 1 8 1
30 4 4 4 16 1 2 8 1
31 4 8 8 16 2 2 8 1
32 2 2 4 32 4 >2 32 2
“A” corresponds to the antibacterial activity gain obtained in the presence of the respective compound and evaluated for each antibiotic (A =MIC without compound/MIC
with compound). DOX, doxycycline; ERY, erythromycin; NAL, nalidixic acid.
FIGURE 2 | Representative isobologram of interactions between compound 32 and nalidixic acid or chloramphenicol. Nalidixic acid, solid line;
chloramphenicol, dotted line. The axis numbers correspond to normalized FICs obtained with Enterobacter aerogenes CM64 strain.
Effect on Chloramphenicol Susceptibility
The results are presented in Table 2. In the case of the
CM 64 strain, compounds tested at the concentration of
0.0625 mM showed a weak chemosensitizing effect on CHL
antibacterial activity compared to PAβN. Compounds of
generation IIIA (29–32) examined at a concentration of 0.5 mM
decreased the chloramphenicol MIC from 2- to 4-fold in
the reference strain and from 4- to 32-fold in the strain
overexpressing eﬄux pump (see ACHL in Table 2). We observed
a noticeable increase in CHL susceptibility in the AcrAB
overproducer CM 64, a 32-fold gain in the susceptibility with
the compound 32 compared to compounds 29–31. In this
assay, the chemosensitizing effect of compound 32 can be
compared to PAβN which was much more active in the strain
overexpressing the AcrAB pump than in the parental strain
ATCC 13048.
Effect on Sparfloxacin Susceptibility
Table 2 presents the effects of hydantoins on sparfloxacin (SPX)
susceptibility. In CM 64, the chemosensitizing effect of low
concentrated hydantoins on SPX was as weak as we observed in
the case of CHL. Compounds of generation IIIA (29–32) tested
at the highest concentration 0.5 mM caused a 4–8-fold decrease
in the MIC in the ATCC 13048 strain and a 2–8-fold decrease
in the MIC in CM 64 one. Comparing the results obtained
for the active compounds (29–32) to the results obtained for
PAβN (see ASPX in Table 2) we observed that the action of
hydantoins with SPX was less efficient than PAβN, which was
more active in the CM64 strain overexpressing the AcrAB pump
than in the reference strain ATCC13048. This may suggest a
different conformational site for the two molecules, either for
recognition or for binding step, in the AcrB monomer (Delmar
et al., 2014; Du et al., 2014; Yamaguchi et al., 2015), inside
the pump or a different mode of action on the resistance
mechanism.
Effect of Compounds 29–32 on the
Resistance Level in MDR E. aerogenes
Strains
In order to evaluate the chemosensitizing effect of the
compounds 29–32 (the most effective molecules) on the MDR
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background, the Ea289 and Ea294 strains were assayed. It
is important to mention that these strains contain various
resistance mechanisms (Malléa et al., 1998; Pradel and Pagès,
2002) such as target mutations (e.g., mutations in QRDR
region of gyrase that increase quinolone resistance) and
expression of modifying enzymes (e.g., ß-lactamases that
contribute to ß-lactam resistance). Table 3 presents the
activity gain parameter A tested with doxycycline (DOX),
erythromycin (ERY), and nalidixic acid (NAL) in parental
and AcrAB-derivative strain context. It is interesting to note
that 32 exhibited significant restoring antibiotic activity with
DOX in Ea289 and very weak action in Ea294 that is
devoid of the AcrAB eﬄux pump components. In contrast,
a weak chemosensitizing activity was observed with ERY,
this effect could be caused by the presence of additional
resistance mechanisms for the macrolide antibiotic class as
previously reported (Chollet et al., 2004). Regarding the
effect on NAL and sparfloxacin susceptibility, the mutations
in the quinolone target (DNA gyrase) previously reported
in Ea289, can explain the weak effect observed toward
these strains (Pradel and Pagès, 2002; Kašcˇáková et al.,
2012).
Determination of the FIC Index for
Compound 32
To precise the type of interaction (synergistic, additive, or
indifferent) between compound 32 and selected antibiotics, we
carried out analysis based on the FICi as previously described.
Combinations of compound 32 with NAL and CHL respectively
were performed in CM 64 strain. This strain overexpresses
the AcrAB pump and does not contain target mutation that
can impair the effect of compounds on the restoration of
antibiotic activity. The nature of the association was determined
from the FICi average obtained from each combination
and the representation was performed for each combination
(Figure 2). In two cases, the isobologram curve obtained was
concave indicating a synergy association between antibiotic and
compound 32. The synergistic association corresponds to an
average of calculated FICi of about 0.32 for NAL and 0.44 for
CHL respectively. These curves fitted well with the Table 2
data.
DISCUSSION
The aim of this study was to identify compounds that are able to
modulate the AcrAB pump activity and restore antibiotic activity
on eﬄux producing strains.
The various molecules combined with NAL and CHL
increased the susceptibility of the CM 64 strain and of the
reference strain ATCC 13048 to antibiotics. On the one
hand, we found compounds that showed stronger activity
in the ATCC 13048 strain than in the CM 64 strain (29–31
tested with NAL, 29, 30 tested with SPX). These findings
could indicate in this case that tested compounds are not
highly selective toward the AcrAB-TolC pump involved
in the eﬄux of antibiotics. This suggests that they act not
only on the basal AcrAB expressing strain but also that they
may recognize other bacterial targets. In contrast, PAβN
combined with CHL and SPX as well as the 3-aminobutyl-5-
β-naphthylhydantoin 32 tested with CHL exhibited a difference
between the AcrAB overproducer strain and the parental
one. This time these results suggest a significant selectivity of
chemosensitizers for the AcrAB pump expressed in bacterial
strains. Taking into account the influence of concentration
of 3-aminoalkyl-5-naphthylhydantoins (generation IIIA) on
the antibiotic activity, we observed that the higher is the
concentration, the stronger is the chemosensitizing effect,
not only on the CM 64 strain but also on ATCC 13048.
These outcomes could suggest additional mechanisms
of action besides the effect on the AcrAB-TolC eﬄux
pump.
The comparison of the results in Ea289 and Ea294 (Table 3)
indicates the correlation of the restoring activity of antibiotics
with the presence of the AcrAB eﬄux pump. They also illustrate
the capability of compound 32 to increase the antibacterial effect
of DOX in these strains. The low effect of 32 on the ERY
susceptibility when assayed in Ea289 and Ea294 can be due
to additional pump, other than AcrB, active in these clinical
derivative strains capable to expel this class of drugs (Chollet
et al., 2004).
The different structural features of tested compounds
allow showing how the nature and the position of their
diverse molecular fragments modulate on the one hand their
selectivity regarding AcrAB pump and on the other hand their
chemosensitizing activity. The tested compounds exhibiting the
common hydantoin scaffold were modified using two of diverse
substituents at position 5 as well as amine substituents and a
selection of linkers to bind an amine to the hydantoin core.
The location of an amine-alkyl fragment at position N1 or N3
to an aryl fragment at position 5 was modified for comparing
with the activity of the first generations of hydantoin synthesized
(Handzlik et al., 2011). In the case of 32, the hydrophilic primary
amine fragment is focused by terminate location at the end
of longer 3-hydantoin substitution, opposite to the 5-β-nahthyl
one.
The most active compounds (29–32) share the same
pharmacophore profile than PAβN suggesting a similar
physicochemical outline for an identical target. The amphiphilic
nature of the Generation IIIA of optimized derivatives seems to
be crucial to inhibit antibiotic resistance mediated by eﬄux pump
and open new ways for generating original active compounds
able to inhibit pump activity. With the recent published data
regarding piperazine arylideneimidazolone derivatives as
potential eﬄux inhibitors in Escherichia coli cells (Bohnert et al.,
2016), the compound 32 characterized in this study will be
used for pharmacophoric modulations in order to develop more
potent inhibitors.
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